PPG, Essilor in talks about Transitions Optical joint venture

Article

Discussions continue about what the future will hold for the Transitions Optical, the joint venture of Essilor International and PPG Industries.

 

Pittsburgh-PPG Industries Inc. continues discussions with Essilor International regarding the future of PPG’s and Essilor’s joint venture (JV), Transitions Optical. PPG is majority shareholder in Transitions Optical, holding a 51% interest in the JV companies. Essilor holds the remaining 49% interest and also is the largest customer of Transitions Optical.

PPG said it cannot predict the outcome of the discussions with Essilor regarding the future of Transitions Optical but believes that possible outcomes may include a modification of the current JV structure, a sale of all or a portion of PPG’s interests in Transitions Optical to Essilor, or a sale of all or a portion of Essilor’s interests in Transitions Optical to PPG.

PPG said it cannot predict the timing of the completion of its discussions with Essilor but expects that these talks are likely to continue over the next several months.

The two shareholders emphasized that their discussions will not impact the day-to-day operations of Transitions Optical. 

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.